These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 19827267)

  • 1. Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics.
    Ishikawa T; Nakagawa H
    J Exp Ther Oncol; 2009; 8(1):5-24. PubMed ID: 19827267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human ABC transporter ABCG2 in cancer chemotherapy: drug molecular design to circumvent multidrug resistance.
    Ishikawa T; Saito H; Hirano H; Inoue Y; Ikegami Y
    Methods Mol Biol; 2012; 910():267-78. PubMed ID: 22821599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the breast cancer resistance protein (ABCG2) in drug transport.
    Mao Q; Unadkat JD
    AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug resistance mediated by ABC transporters].
    Yoshikawa M; Ito A; Ishikawa T; Ikegami Y
    Gan To Kagaku Ryoho; 2004 Jan; 31(1):1-6. PubMed ID: 14750312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular pharmacology of ABCG2 and its role in chemoresistance.
    Stacy AE; Jansson PJ; Richardson DR
    Mol Pharmacol; 2013 Nov; 84(5):655-69. PubMed ID: 24021215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.
    Han B; Zhang JT
    Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):31-42. PubMed ID: 14754410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABCG2: a perspective.
    Robey RW; To KK; Polgar O; Dohse M; Fetsch P; Dean M; Bates SE
    Adv Drug Deliv Rev; 2009 Jan; 61(1):3-13. PubMed ID: 19135109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    Pick A; Wiese M
    ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L; Ross DD
    Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).
    Meyer zu Schwabedissen HE; Kroemer HK
    Handb Exp Pharmacol; 2011; (201):325-71. PubMed ID: 21103975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer resistance protein (BCRP/ABCG2).
    Staud F; Pavek P
    Int J Biochem Cell Biol; 2005 Apr; 37(4):720-5. PubMed ID: 15694832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.
    Lepper ER; Nooter K; Verweij J; Acharya MR; Figg WD; Sparreboom A
    Pharmacogenomics; 2005 Mar; 6(2):115-38. PubMed ID: 15882131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity.
    Xu J; Peng H; Chen Q; Liu Y; Dong Z; Zhang JT
    Cancer Res; 2007 May; 67(9):4373-81. PubMed ID: 17483351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions.
    Saito H; Hirano H; Nakagawa H; Fukami T; Oosumi K; Murakami K; Kimura H; Kouchi T; Konomi M; Tao E; Tsujikawa N; Tarui S; Nagakura M; Osumi M; Ishikawa T
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1114-24. PubMed ID: 16489126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2.
    Wu CP; Hsiao SH; Su CY; Luo SY; Li YQ; Huang YH; Hsieh CH; Huang CW
    Biochem Pharmacol; 2014 Dec; 92(4):567-76. PubMed ID: 25450670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2.
    Nakagawa H; Tamura A; Wakabayashi K; Hoshijima K; Komada M; Yoshida T; Kometani S; Matsubara T; Mikuriya K; Ishikawa T
    Biochem J; 2008 May; 411(3):623-31. PubMed ID: 18237272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging new technology: QSAR analysis and MO Calculation to characterize interactions of protein kinase inhibitors with the human ABC transporter, ABCG2 (BCRP).
    Saito H; An R; Hirano H; Ishikawa T
    Drug Metab Pharmacokinet; 2010; 25(1):72-83. PubMed ID: 20208390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QSAR analysis and molecular modeling of ABCG2-specific inhibitors.
    Nicolle E; Boumendjel A; Macalou S; Genoux E; Ahmed-Belkacem A; Carrupt PA; Di Pietro A
    Adv Drug Deliv Rev; 2009 Jan; 61(1):34-46. PubMed ID: 19135106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.